Study on Cabozantinib Combined with PD-1 and CTLA-4 Inhibition for Metastatic Soft Tissue Sarcoma

Inclusion Criteria

• Have a confirmed diagnosis of metastatic or inoperable soft tissue sarcoma.
• Have tumors that can be measured by scans or physical exams.
• Have tried at least one but no more than two previous treatments, with the cancer worsening after the last treatment.
• Be 18 years or older.
• Be in good general health, with a performance status score of 0 or 1.
• Have normal blood and organ function based on specific medical tests.
• Be willing to use effective birth control during the study and for several months after the last treatment dose.
• Be able to understand and sign a consent form to participate in the study.

Exclusion Criteria

• Have a type of sarcoma driven by specific genetic changes, except for alveolar soft part sarcoma.
• Have previously been treated with cabozantinib or similar immunotherapy drugs.
• Have another type of cancer, unless it was treated and resolved at least two years ago.
• Have active brain metastases or other serious medical conditions that could interfere with the study.
• Be currently receiving other investigational treatments or medications that could affect the study.
• Have had recent major surgery or radiation therapy that has not fully healed.
• Be pregnant or breastfeeding, or planning to become pregnant during the study.
• Have received a live vaccine within 30 days before starting the study.